Date:10/28/2009

498 (1,119) ------- ------- Net cash provided by operating activities 11,678 4,592 ------- ------- Cash flows from investing activities: Capital expenditures (7,119) (12,293) Acquisition of leasehold improvements - 327 Payments for technology licenses (1,500) - Cost of acquisition, net (148) - Proceeds from sale and maturities of marketable securities and short-term investments 100 2,550 Proceeds from the sale of fixed assets 16 125 Transfer to unrestricted cash 1,500 517 ------- ------- Net cash used in investing activities (7,151) (8,774) ------- ------- Cash flows from financing activities: Net proceeds from the issuance of common shares and exercise of stock options and awards 5,174 11,977 Principal payments of bank borrowing (40) - Principal payments of notes payable - (4) ------- ------- Net cash provided by financing activities 5,134 11,973 ------- ------- Effect of exchange rate change on cash 202 122 ------- ------- Net increase in cash and cash equivalents 9,863 7,913 Cash and cash equivalents at beginning of period 23,478 16,47
'/>"/>

SOURCE Cepheid Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
2. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
3. Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized Moderate Complexity by FDA
4. Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection
5. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
6. Cepheid Launches New GeneXpert(R) Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus
7. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
10. Endologix Reports 47% Third Quarter 2009 Revenue Growth
11. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results